Source comparison
CJC-1295 (No DAC) vs CJC-1295 (With DAC): Research Application Comparison
Half-Life ~30 minutes 6–8 days The DAC modification extends retention by 300× through albumin binding Dosing Frequency 2–3× daily 1–2× weekly Non-DAC requires frequent administration to sustain GH pulses Peak GH Pulse Timing 15–30 minutes post-injection 2–4 ho
This comparison does not assign a generated winner or score.
- Half-Life
- ~30 minutes
- 6–8 days
- The DAC modification extends retention by 300× through albumin binding
- Dosing Frequency
- 2–3× daily
- 1–2× weekly
- Non-DAC requires frequent administration to sustain GH pulses
- Peak GH Pulse Timing
- 15–30 minutes post-injection
- 2–4 hours post-injection, with smaller pulses for 6–8 days
- Non-DAC produces sharp, brief pulses; DAC produces sustained elevation
- Typical Research Dose Range
- 100–200 mcg per administration
- 30–60 mcg/kg weekly or biweekly
- Non-DAC uses lower absolute doses but higher frequency
- Common Pairing Strategy
- Often combined with GHRP-2, GHRP-6, or ipamorelin for synergistic GH release
- Used alone or with growth hormone secretagogues
- Non-DAC benefits from secretagogue co-administration
- Primary Advantage
- Mimics natural pulsatile GH release pattern without long-term accumulation
- Convenient dosing with sustained IGF-1 elevation
- DAC suits compliance-focused protocols; non-DAC suits pulsatile studies